Author: biocytogen

Tumor Models Boston 2022

June 9, 2022

Attend the meeting Talk to us As the only industry-led meeting dedicated to preclinical and translational targeted oncology modeling, driven by case studies, enabling our audience to make informed clinical decisions – this is your must attend event in 2022. With 2022 being free to attend for drug developers and academics, now is your chance […]

Read More

EACR 2022 Congress

June 7, 2022

EACR 2022 is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations. The European Association for Cancer Research (EACR) is a non-profit membership association dedicated […]

Read More

Biocytogen Europe Innovation Center Team to Present at AET-EU 2022, Introducing Project Integrum, TCR-mimic Platform and YH012

June 3, 2022

Beijing and Heidelberg, June 3, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) today announced 3 poster presentations for two novel fully human antibody platforms and one bispecific antibody-drug conjugate (ADC) asset at the 2022 Antibody Engineering & Therapeutics Europe (AET-EU) meeting, taking place on June 7-9 in Amsterdam and online. The antibody business development […]

Read More

Webinar: Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery

June 1, 2022

Our webinar “Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery” was live on June 22, 2022 at 1PM EDT. In this webinar, we Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate […]

Read More

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022

Beijing, China, May 24, 2022 /PRNewswire/ — Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and virtually from June 3-7, 2022. The posters describe updates from two phase I clinical studies […]

Read More

HBHL Symposium 2022

May 18, 2022

Attend the meeting Talk to us Healthy Brains, Healthy Lives (HBHL) is an interdisciplinary program, built on McGill’s global leadership in interdisciplinary neuroscience, that uses big data analysis to reveal the fundamental mechanisms underlying normal brain function and brain disorders. HBHL aims to accelerate translational discoveries and create a global centre of excellence in neuroinformatics […]

Read More

15th Canadian Neuroscience Meeting

May 11, 2022

Attend the meeting Talk to us at Tabletop T08 The Canadian Association for Neuroscience (CAN) is the largest association of neuroscientists in Canada. Our members dedicated to advancing brain research. Our association is composed of over one thousand researchers, who work at academic institutions across the country. We share the common goal of ensuring neuroscience […]

Read More

Immunology 2022

May 4, 2022

Poster Session Poster number: P620 Title: RenMice™ HiTS Platform Enables Identification of Novel Therapeutic Antibodies Date: Sunday, May 8, 2022 Time: 2:30 PM – 3:45 PM PDT Presenter: Jenna Frame, PhD, Scientific Communications & Marketing, Biocytogen Boston Attend the meeting Agenda Talk to us at booth 237! The largest annual immunology event worldwide, the AAI annual […]

Read More

Biocytogen Enters into Antibody Agreement with Merck

April 29, 2022

BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date […]

Read More

Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene

April 25, 2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite® mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs. RenMab™ and RenLite® mice, which have proprietary intellectual property rights, were developed by […]

Read More

Back to top